BioVie Announces First Patient Enrolled in Phase 3 Study of NE3107 in Alzheimer’s Disease

BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug candidates for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers,